Using genome editing technology based on TALEN and the CRISPR/Cas9 system, a group around Akutsu HOTTA succeeded to repair the dystrophin gene („exon 45 skipping“) in iPS cells derived from a DMD patient.

JST news release, Nov. 27, 2014